| Name | Tenofovir alafenamide fumarate |
| Description | Tenofovir alafenamide fumarate (GS-7340 fumarate) is an orally available precursor of Tenofovir with anti-HIV activity, used to prevent HIV infection. |
| In vitro | Tenofovir alafenamide fumarate antiviral activity was similar in all cell types, ranging from 5 to 7 nM, whereas CC50 varied from 4.7 to 42 μM for MT-4 and MT-2 cells. The antiviral activity of TAF was evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 M group subtypes A to G, as well as group N and O isolates. Overall, TAF EC50 ranged from 0.1 to 12 nM, with an average EC50 of 3.5 nM, compared to an average EC50 of 11.8 nM for AZT, used as an internal control, for 29 major HIV-1 isolates tested in PBMC. For HIV-2 isolates, the average EC50 is 1.8 nM for TAF and 6.4 nM for AZT.[2] |
| In vivo | Tenofovir alafenamide fumarate (GS-7340 fumarate), an amidate prodrug of Tenofovir, exhibits enhanced oral bioavailability and plasma stability compared to Tenofovir disoproxil fumarate (TDF) [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 25 mg/mL (42.19 mM), Sonication is recommended.
DMSO : 200 mg/mL (337.53 mM), Sonication is recommended.
|
| Keywords | Tenofovir alafenamide Fumarate | GS-7340 Fumarate | GS7340 Fumarate | GS 7340 Fumarate |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Kaempferol | Dolutegravir intermediate-1 | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Chloroquine phosphate | Decanedioic acid | Tenofovir |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max |
United States
